How Government Policies Influence Generic Drug Availability

Introduction

Generic medicines are the backbone of affordable healthcare in India. With nearly 70% of medicines consumed in the country being generics, they play a vital role in making treatments accessible to millions. But have you ever wondered how the government ensures that these medicines remain affordable and available? The answer lies in various policies, regulations, and price controls set by authorities.

For instance, pharmaceutical companies in Gujarat are some of the biggest manufacturers of generic drugs in India, contributing significantly to both domestic supply and exports. Gujarat alone accounts for 33% of India’s total pharmaceutical production and about 28% of exports. With strong government policies supporting the production and pricing of generic medicines, India remains one of the world's largest suppliers of affordable drugs.

Let’s dive deep into how government policies influence generic drug availability and pricing.

Government Regulations & Pricing Policies

1. Drug Price Control Order (DPCO) & NPPA

One of the biggest concerns with medicines is pricing. The Indian government regulates drug prices through the Drug Price Control Order (DPCO), managed by the National Pharmaceutical Pricing Authority (NPPA).

• The NPPA ensures that essential medicines remain affordable for common people.
• Under DPCO, the government sets ceiling prices for over 800 essential medicines, including life-saving drugs like antibiotics, insulin, and cardiovascular medicines.
• In 2023, NPPA slashed prices of 40 essential drugs, making treatments for diabetes, hypertension, and other conditions cheaper.

Without such policies, the cost of generic medicines would fluctuate based on market trends, making them less accessible to low-income populations.

2. Jan Aushadhi Scheme & Affordable Generics

To make generics more accessible, the Indian government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP).

• Over 9,500 Jan Aushadhi Kendras have been set up across India.
• These stores provide generic medicines at prices 50-90% lower than branded drugs.
• Example: A branded Atorvastatin tablet (for cholesterol) costs around ₹80 per strip, while the generic version at Jan Aushadhi Kendras costs only ₹15-20.

This initiative has helped millions access quality medicines at affordable rates, especially in rural and semi-urban areas.

3. GST Impact on Generic Medicines

Goods and Services Tax (GST) has significantly influenced drug pricing.

• Generic medicines are taxed at 5% GST, whereas some branded drugs attract 12% GST.
• Lower GST on generics makes them more affordable compared to expensive branded alternatives.
• However, some industry experts argue that removing GST on essential generic medicines could further reduce prices.
• 
  

Regulatory Approvals & Quality Standards

4. CDSCO & WHO-GMP Compliance

The Central Drugs Standard Control Organization (CDSCO) regulates drug approvals in India. For a generic drug to be available in the market, it must meet strict quality standards.

• All pharmaceutical companies must comply with Good Manufacturing Practices (GMP).
• WHO-GMP certification is mandatory for companies looking to export medicines to global markets.
• Gujarat, being a major pharmaceutical hub, has over 600 WHO-GMP-certified manufacturing units, ensuring high-quality production.

5. Government Support for R&D in Generics

To boost domestic manufacturing, the government has introduced several schemes, including:

• Production Linked Incentive (PLI) Scheme – Encourages pharmaceutical companies to invest in research and development of high-quality generics.
• API (Active Pharmaceutical Ingredients) Promotion – Reducing dependency on China by encouraging local production of APIs.

Patent Laws & Impact on Generic Drug Availability

6. Indian Patent Act & Compulsory Licensing

Unlike many Western countries, India has a strong patent law that allows the production of affordable generics.

• The Indian Patent Act of 1970 does not allow "evergreening" of patents, which prevents big pharma companies from extending patents unnecessarily.
• India has granted compulsory licenses for expensive medicines, allowing local pharma companies to manufacture generics at lower costs.
• Example: In 2012, India issued a compulsory license for Nexavar, a cancer drug, reducing its price from ₹2.8 lakh per month to ₹8,800 per month.

7. TRIPS Agreement & India’s Stance

India is a signatory to the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement under WTO.

• While TRIPS mandates strict patent laws, India has used its provisions to ensure medicines remain affordable.
• Many countries import generic medicines from India because of its flexible patent laws.

The Role of Make in India & Pharma Exports

8. Government’s Push for Generics through Make in India

The Make in India initiative has played a huge role in boosting domestic pharmaceutical manufacturing.

• India’s pharma industry is worth $50 billion, with generics contributing nearly 70%.
• Policies supporting domestic production have reduced India's dependence on imports.
• Gujarat is leading the way, with major companies like Cadila, Zydus, and Intas Pharmaceuticals producing high-quality generics for both domestic and export markets.

9. Export Incentives for WHO-GMP Certified Manufacturers

The government provides export incentives for WHO-GMP-certified pharma companies to promote generic medicines worldwide.

• India exports $24 billion worth of pharmaceuticals annually.
• The top export destinations include USA, Europe, Africa, and Southeast Asia.
• Government schemes like Remission of Duties and Taxes on Exported Products (RoDTEP) ensure pharma companies remain competitive in global markets.

Challenges & Future Outlook

10. Challenges in Regulatory Approvals

While policies support generic drug manufacturing, challenges remain:

• Lengthy approval processes for new generics.
• High compliance costs for small manufacturers.
• Quality control issues in smaller pharma firms.

11. Future Government Initiatives for Generics

To address these challenges, the government is planning:

• Stronger enforcement of quality standards for generic medicines.
• Expansion of Jan Aushadhi Kendras to rural areas.
• Investment in digital health records to promote generic prescriptions.

Conclusion

Government policies have played a crucial role in making generic medicines widely available and affordable in India. From price control regulations to quality compliance, these policies ensure that essential drugs reach those who need them the most. With initiatives like Jan Aushadhi Kendras, WHO-GMP certification, and the Make in India campaign, India continues to strengthen its position as the “Pharmacy of the World.”

As consumers, we should be aware of these policies and choose generic medicines whenever possible, ensuring both affordability and quality in healthcare. The future of India's pharmaceutical sector looks promising, and with continued government support, generic medicines will remain the key to accessible healthcare for all.